Show results for
Refine by
Cancer Target Equipment & Supplies In Romania
109 equipment items found
Premium
Manufactured by:Vobis LLC based inEaston, PENNSYLVANIA (USA)
We have developed proprietary lipid based nano technologies that have potential benefits in different therapeutic areas including targeted cancer therapy, DNA Vaccination and liver diseases. Here are the some of the highlights related to our LNP and liposomal experience including type of liposomes and techniques. ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: New Formulation. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12014/EGI014 Trastuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG1206A Pertuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: Phase ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
by:Genmab A/S based inCopenhagen V, DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including 61Cu for diagnostics and 67Cu for therapeutics, are integral in developing highly precise ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI refined and improved ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and exert bi-modal proliferative inhibition, any cancer ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTRACE is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive and if so, how it should be treated. uTRACE has been tested on over 400 patients in several cancer forms and proven to be ...
Manufactured by:Reglagene Holding, Inc. based inTucson, ARIZONA (USA)
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers. ...
Manufactured by:SurgiMab based inMontpellier, FRANCE
SGM-201 is a preclinical stage product based on the same technique that targets ovarian cancer. Both allow surgeons to visualize tumors in real-time with a near-infrared camera, helping them to perform more radical cytoreductive surgery, thus automatically improving surgical outcomes. ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTREAT is new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, including the metastases that are far away from the primary tumour, this offers a personalised and tailored therapy to each ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged stimulation, P2X7 can form a membrane pore that’s ...
Manufactured by:CMR Naviscan Corporation based inCarlsbad, CALIFORNIA (USA)
The Solo II™ Breast PET scanner (also called positron emission mammography or PEM) produces high-resolution images, with far more detail than conventional breast imaging. By producing tomographic images of lesions with resolution down to 1.6 mm (approximately the size of a grain of rice), this technology provides valuable clinical data on invasive and non-invasive disease across the ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical areas for diagnosis and/or therapy. Targeted radiopharmaceuticals bind to specific structures such as proteins or cells within the body and thus accumulate in particular places, such as e.g. tumor lesions in a cancer ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen receptors (CAR’s) on the cell surface. The chimeric antigen receptors give T cells the ability to target cancer cells. They comprise two specific components: one, an antibody fragment allowing CARs to identify ...